As a naturally occurring peptide fragment, BPC-157 also lacks strong patent protection, which has likely reduced commercial incentive to fund the trials needed for FDA approval
The first is extracellular matrix biology, where fibroblast culture and rat wound-chamber studies from the Maquart and Simeon groups (1988-2000) reported stimulation of collagen synthesis, sulfated glycosaminoglycan synthesis and small proteoglycan expression, alongside upregulation of matrix metalloproteinase-2 and its tissue inhibitors, a simultaneous increase in both matrix deposition and matrix turnover
BPC-157 CAS: 137525-51-0 | TB-500 CAS: 77591-33-4
Vaccines Before commencing immunomodulators and biologic therapy, all patients should: be screened for latent infections, including hepatitis B, hepatitis C, HIV infection and tuberculosis have their immunity to vaccine-preventable infections confirmed, particularly infections that require live vaccines, as these may be contraindicated in patients receiving immunosuppressant therapy